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Abstract PTP-S2/TC45 is a nuclear protein tyrosine phospha-
tase, which induces p53-dependent apoptosis. Here we show that
the p53 protein level increased in MCF-7 cells in response to
PTP-S2 overexpression. PTP-S2-induced p53 protein was tran-
scriptionally active and it could activate caspase-1 gene expres-
sion from endogenous as well as ectopic promoter. Coexpression
of an active site mutant of procaspase-1 strongly inhibited PTP-
S2-induced apoptosis. Mutant procaspase-1 also inhibited apo-
ptosis induced by p53 overexpression or doxorubicin treatment,
which induce caspase-1 gene expression. In contrast, apoptosis
induced by staurosporine or cycloheximide, which do not in-
crease caspase-1 gene expression, was not a¡ected by mutant
procaspase-1. These results suggest that caspase-1 may be one
of the mediators of p53-dependent apoptosis in human cells.
+ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The tumor suppressor protein p53 plays an important role
in mediating a response to stress such as that induced by
DNA damage or hyperproliferative signals resulting in either
growth arrest or apoptosis [1]. The apoptosis inducing activity
of p53 is a major contributor to its tumor suppressor function
[2]. p53 protein has a high turnover rate and is maintained at
very low levels under normal conditions. Upon exposure to
various stimuli p53 is activated through post-translational
modi¢cations that increase both its stability and activity [3].
Activated p53 is a sequence-speci¢c DNA-binding protein,
which functions as a transcription factor. It is generally be-
lieved that many genes regulated transcriptionally by p53 me-
diate p53-dependent apoptosis. These p53 targets include
BAX, p53AIP, Noxa, PUMA, PIGs, Apaf-1, PIDD, Fas,
Killer/DR5 etc. [4]. Recently, we have shown that human
caspase-1 is a direct transcriptional target of p53 [5].
PTP-S2/TC45 is a ubiquitously expressed nuclear protein
tyrosine phosphatase, which binds to DNA non-speci¢cally
[6]. Mitogenic stimulation of a variety of cells increases the
PTP-S2 mRNA level transiently in G1 phase suggesting a role
for this phosphatase in a process related to cell proliferation
[6,8,9]. Overexpression of PTP-S2 at moderate levels promotes
progression of cells through G1 to S phase in HeLa cells
[10,11]. PTP-S2 overexpression at high levels by transient
transfections induces apoptosis in p53-positive cells but not
in p53-negative cells [12]. Overexpression of PTP-S4/TC48 (a
splice variant of PTP-S2 which di¡ers from PTP-S2 in sub-
cellular location, substrate speci¢city and other properties)
induces much less apoptosis in p53-positive cells. PTP-S2-
induced apoptosis is inhibited by coexpression of His 273
mutant of p53 [12]. Since mutant p53 (273 His) carries a
mutation in sequence-speci¢c DNA-binding region, these ob-
servations suggest that PTP-S2-induced apoptosis requires
transcriptional activation function of p53 dependent on se-
quence-speci¢c DNA-binding. However, the role of p53 in
PTP-S2-induced apoptosis is not known.
Here we have analyzed the role of p53 and caspase-1 in
PTP-S2-induced apoptosis. Our studies show that PTP-S2 ex-
pression leads to an increase in the level and activity of p53
protein. PTP-S2 expression results in an increase in caspase-1
mRNA level and caspase-1 promoter activity in a p53-depen-
dent manner. Our results suggest that PTP-S2-induced cas-
pase-1 gene transcription, mediated by p53, contributes to
apoptosis in human tumor cell lines. In addition, we show
that caspase-1 contributes to p53-induced apoptosis.
2. Materials and methods
2.1. Expression vectors and antibodies
Human procaspase-1 cDNA (K-form) was ampli¢ed by reverse
transcription polymerase chain reaction (RT-PCR) using RNA from
HeLa cells. It was cloned in pCB6þ expression vector in the EcoRI
site. Mutant procaspase-1 was prepared by replacing Cys 285 (TGC)
with Ala (GCC) by PCR-based site-directed mutagenesis. The nucle-
otide sequence of the mutant and wild-type procaspase-1 cDNA was
con¢rmed by automated sequencing. Plasmids for expressing PTP-S2
(induced by removal of tetracycline) have been described previously
[10]. Plasmids expressing p73DD and p53DD, speci¢c inhibitors of
p73 and p53, respectively [13], were kindly provided by Dr. W.G.
Kaelin, Harvard Medical School, USA. The antibodies used were:
p53 antibody, goat polyclonal from Roche Molecular Biochemicals,
Cdk-2 and caspase-1, Santa Cruz Biotechnology. PTP-S2 monoclonal
antibody has been described previously [7]. T7 tag antibody was from
Novagen.
2.2. Cell culture, transfections and immuno£uorescence staining
The cell lines were maintained at 37‡C in a CO2 incubator in Dul-
becco’s modi¢ed Eagle’s medium supplemented with 10% fetal calf
serum. The transfections were done using Lipofectamine Plus1 re-
agent (Life Technologies, Inc.) according to the manufacturer’s in-
structions. All the plasmids for transfection were prepared by using
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Qiagen columns. For immuno£uorescence staining, cells grown on
coverslips were transfected with the required plasmids, ¢xed after 24
or 48 h and stained with required antibodies as described earlier [6].
2.3. Reporter plasmids and reporter assays
The reporter plasmid pCAT-ICE-WT which contains human cas-
pase-1 promoter from 3182 to +42 relative to the transcription start
site cloned upstream of chloramphenicol acetyltransferase (CAT) re-
porter gene has been described [14]. The reporter plasmid pCAT-ICE-
MT was derived from pCAT-ICE-WT by mutating the p53-responsive
site [5]. Cells grown in 60 mm dishes were transfected with 500 ng of
pCAT-ICE-WT (or pCAT-ICE-MT), 200 ng of pCMV-SPORT-L-Gal
(Life technologies, Inc.) and 750 ng each of pTRE-PTP-S2 and pTet-
O¡ plasmids, or control plasmids. Preparation of lysates and CAT
assays were carried out as described [5].
2.4. Apoptosis assay
Quantitative analysis of apoptotic cells was carried out essentially
as described previously [12]. Cells grown on coverslips were trans-
fected with the required plasmids and processed for immuno£uores-
cence staining using appropriate antibodies. For caspase-4-induced
apoptosis, GFP plasmid was included to visualize transfected cells.
Cells were mounted in 90% glycerol containing 1 mg/ml paraphe-
nylenediamine (antifade) and 0.5 Wg/ml DAPI (4P,6-diamidino-2-phe-
nylindoledihydrochloride) to stain the DNA. Cells showing immuno-
£uorescence staining were counted and those cells that showed loss of
cell volume, loss of refractility and condensed chromatin were scored
as apoptotic. At least 200 expressing cells were counted in each cover-
slip. The data represent meanSS.D. from at least three independent
experiments. Cells not expressing the transfected protein were also
counted in each coverslip. Generally 1^3% of non-expressing cells
showed apoptosis.
2.5. RT-PCR
Total RNA was isolated using Trizol1 reagent (Life Technologies,
Inc.). Semiquantitative RT-PCR was carried out essentially as de-
scribed previously [5,6]. RNA was reverse-transcribed using reagents
from ¢rst strand cDNA synthesis kit (Life Technologies, Inc.). The
caspase-1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
mRNAs were ampli¢ed in the same reactions for 40 and 23 cycles,
respectively. Primers for ampli¢cation of caspase-1 and GAPDH have
been described previously [5,6]. Appropriate gene-speci¢c primers
were used for ampli¢cation of various caspases and other genes.
3. Results and discussion
3.1. Activation of p53 upon overexpression of PTP-S2
PTP-S2 overexpression in MCF-7 cells was achieved by
transient transfection of pTet-O¡ and pTRE-S2 (PTP-S2
cloned in pTRE) plasmids. Twenty-four hours after transfec-
tion cells were trypsinized and plated on two plates: one in-
duced (by removal of tetracycline) and the other one unin-
duced. The cells were harvested after 24 h of induction. PTP-
S2 expression upon induction was con¢rmed by immunoblot
using PTP-S2 monoclonal antibody G11 (Fig. 1A). This
monoclonal antibody recognizes rat or mouse PTP-S2 protein
but not the endogenous human protein [6,7]. The level of p53
protein markedly increased upon expression of PTP-S2 in
MCF-7 cells (Fig. 1A). Equal loading of protein on the im-
munoblot was con¢rmed by reblotting the membrane with
Cdk-2 antibody (Fig. 1A). The half-life of PTP-S2-induced
p53 protein was about 2 h as determined by treatment of cells
with protein synthesis inhibitor cycloheximide (Fig. 1A). The
half-life of p53 protein in uninduced cells could not be deter-
mined due to the very low level of this protein. The half-life of
p53 in MCF-7 cells has been reported to be about 30 min [15]
indicating that PTP-S2 overexpression may be stabilizing the
p53 protein. There was no increase in the p53 mRNA upon
PTP-S2 overexpression in MCF-7 cells as determined by semi-
quantitative RT-PCR analysis (Fig. 1B). These results suggest
that induction of p53 protein by PTP-S2 occurred by a post-
transcriptional mechanism. Genes that enhance proliferation
are known to induce p53 through induction of p14ARF [16],
but a PTP-S2-induced increase in p53 protein is likely to be
through a p14ARF-independent pathway since MCF-7 cells
lack p14ARF function due to a deletion in the gene [17].
To analyze whether the PTP-S2-mediated upregulation of
endogenous p53 leads to the activation of p53 transcriptional
function, we determined the level of p21 mRNA which is a
known transcriptional target of p53. For this purpose, we
used MCF-7 cells and MCF-7-mp53, a clone of MCF-7 cells
expressing His 273 mutant of p53. The MCF-7-mp53 clone
was obtained by transfection of MCF-7 cells with His 273
mutant of p53 followed by selection in G418 [5]. This mutant
of p53 has been shown to act as dominant inhibitor of wild-
type p53 function [18]. Induction of PTP-S2 expression after
transient transfection resulted in an increase in p21 mRNA in
MCF-7 cells, but not in MCF-7-mp53 cells (Fig. 1C). These
results showed that p53 protein induced by PTP-S2 expression
is transcriptionally active.
3.2. Induction of caspase-1 gene expression by PTP-S2
Caspase-1 gene expression in human cells is regulated by
p53 [5]. Since PTP-S2-induced apoptosis was p53-dependent,
we analyzed the expression of caspase-1 in MCF-7 cells in
response to PTP-S2 expression. The caspase-1 mRNA level
was very low and it increased several fold in MCF-7 cells
by induction of PTP-S2 expression as compared with unin-
duced cells (Fig. 2). There was no increase in caspase-1
mRNA level upon PTP-S2 overexpression in MCF-7-mp53
cells (Fig. 2). These results suggested that the induction of
caspase-1 mRNA by PTP-S2 expression was dependent on
functional p53 protein. There are ¢ve isoforms of human cas-
pase-1, which di¡er in their apoptotic activities [19]. Using
appropriate primers we determined that the pro-apoptotic
K-isoform of caspase-1 was upregulated upon PTP-S2 over-
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Fig. 1. PTP-S2-induced increase in p53 protein level. A: MCF-7
cells were transfected with PTP-S2 and were induced or uninduced
for PTP-S2 expression. The treatment with 25 Wg/ml cycloheximide
(Chx) was done for 30^120 min. Immunoblotting of total protein
was performed using antibodies against PTP-S2, p53, and Cdk-2. B:
RT-PCR analysis of total RNA isolated from MCF-7 cells, induced
(ind) and uninduced (unind) for PTP-S2 expression. RT products
were used as a template to amplify human p53 and GAPDH
mRNAs using gene-speci¢c primers for human p53 and GAPDH.
An ethidium bromide-stained agarose gel with indicated PCR prod-
ucts is shown. C: RT-PCR analysis of total RNA isolated from
MCF-7 and MCF-7-mp53 cells, induced (ind) and uninduced (unind)
for PTP-S2 expression using primers for p21 and GAPDH.
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expression and other forms were not induced (data not
shown). Expression of p53 also induced only the K-isoform
of caspase-1 [5]. We analyzed the level of mRNA of some
other caspases in response to PTP-S2 overexpression. There
was no increase in the level of caspase-2, caspase-3, caspase-4,
caspase-5, caspase-6, caspase-7, caspase-8, caspase-9 or cas-
pase-10 mRNAs. There was some decrease in the level of
caspase-4, caspase-5 and caspase-9 mRNA, which was p53-
dependent (Fig. 2). These results suggest that p53-dependent
induction of caspase-1 gene expression upon overexpression of
PTP-S2 is a very speci¢c e¡ect and not a general e¡ect on
caspase gene expression.
Multiple transcriptional targets are believed to be involved
in mediating p53-induced apoptosis [3,4,20]. Therefore we an-
alyzed the level of mRNA of some of the known pro-apopto-
tic genes in response to expression of PTP-S2. Apaf-1 was
induced upon PTP-S2 expression in MCF-7 cells but not in
MCF-7-mp53 cells (Fig. 2). There was no signi¢cant increase
in BAX or PUMA mRNA in both MCF-7 and MCF-7-mp53
cells upon PTP-S2 expression although doxorubicin treatment
increased the BAX and PUMA mRNA level in MCF-7 cells
(Fig. 2).
3.3. PTP-S2-induced transactivation of caspase-1 promoter
requires p53
We tested whether PTP-S2-induced accumulation of endog-
enous p53 leads to transactivation of human caspase-1 pro-
moter^reporter construct. To this end, we carried out CAT
reporter assays in transiently transfected MCF-7 cells. As
shown in Fig. 3A, PTP-S2 (and p53) activated the reporter
construct having a wild-type p53-binding site (pCAT-ICE-
WT) but not the reporter construct where the p53-binding
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Fig. 3. Transactivation of caspase-1 promoter by PTP-S2 overex-
pression. A: E¡ect of disruption of the p53-binding site in caspase-1
promoter on its transactivation by PTP-S2. The wild-type pro-
moter^reporter (pCAT-ICE-WT) or mutant promoter^reporter plas-
mid (pCAT-ICE-MT) was cotransfected with pCMV-SPORT-L-Gal
and PTP-S2 (pTRE-S2), wild-type p53 (Wp53) or control plasmids
in MCF-7 cells. CAT activities relative to control (pTRE) are
shown (n=3). B: pCMV-SPORT-L-Gal plasmid and pCAT-ICE-
WT plasmids were cotransfected, along with PTP-S2 (pTRE-S2) or
control (pTRE) plasmids in MCF-7-mp53 cells. CAT activities rela-
tive to control (pTRE) are shown (n=3). C: Expression of PTP-S2
in MCF-7 and MCF-7-mp53 cells. Immunoblotting was performed
with total proteins isolated from MCF-7 and MCF-7-mp53 cells, in-
duced (ind) and uninduced (unind) for PTP-S2 expression using anti-
bodies against PTP-S2, and Cdk-2.
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Fig. 2. PTP-S2 induces caspase-1 gene expression in a p53-depen-
dent manner. RT-PCR analysis of total RNA isolated from MCF-7
and MCF-7-mp53 cells, induced (ind) and uninduced (unind) for
PTP-S2 expression after transient transfection. RT products were
used as a template to amplify indicated mRNAs using respective
gene-speci¢c primers. Ethidium bromide-stained agarose gel with in-
dicated PCR products is shown. Doxorubicin (Dox)-treated and un-
treated (C) controls are shown for BAX, Apaf-1 and PUMA.
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site was abolished by mutation (pCAT-ICE-MT). PTP-S2 ex-
pression was unable to transactivate pCAT-ICE-WT con-
struct in MCF-7-mp53 cells ; instead, there was some decrease
in promoter activity upon PTP-S2 expression (Fig. 3B). This
di¡erence in activation of pCAT-ICE-WT by PTP-S2 in the
two cell lines was not due to variation in the levels of exoge-
nously expressed PTP-S2 protein (Fig. 3C). These results
showed that PTP-S2-induced transcriptional activation of hu-
man caspase-1 promoter was through a p53-binding site and
was dependent on the functional p53 protein in the cell.
Previously, it has been shown that PTP-S2 expression does
not induce apoptosis in HeLa cells [12], which are functionally
p53-negative. In these cells, caspase-1 mRNA was not induced
by PTP-S2 (data not shown). For most of our experiments
described here we have used MCF-7 and MCF-7-mp53 cell
lines. Therefore, we analyzed the extent of apoptosis in MCF-
7-mp53 cells upon PTP-S2 expression. PTP-S2-induced apo-
ptosis was drastically reduced in MCF-7-mp53 cells in which
caspase-1 mRNA was not induced by PTP-S2 (data not
shown).
The p53 homologue, p73, is an inducer of apoptosis, which
activates transcription of many p53-responsive genes such as
p21, mdm2, BAX and GADD45 [21]. To address the role of
p73 in PTP-S2-induced apoptosis we used p73DD and
p53DD, which are speci¢c inhibitors of p73 and p53, respec-
tively [13]. PTP-S2-induced apoptosis was inhibited by co-
transfection with p53DD but not by p73DD (Fig. 4A). This
was not due to a lower level of expression of p73DD (Fig.
4B). This experiment showed that p73 is not required for
PTP-S2-induced apoptosis.
3.4. Requirement of caspase-1 for p53-dependent apoptosis
Since caspase-1 gene expression was increased upon PTP-S2
expression in a p53-dependent manner we analyzed the role of
caspase-1 in PTP-S2-induced as well as p53-induced apopto-
sis. For this purpose a catalytically inactive mutant of human
procaspase-1 was prepared by replacing active site cysteine
with alanine. This Ala 285 mutant of procaspase-1 inhibited
caspase-1-induced apoptosis but not caspase-3- or caspase-4-
induced apoptosis suggesting that it is a speci¢c inhibitor (Fig.
5A). PTP-S2-induced apoptosis in MCF-7 cells was strongly
inhibited by coexpression of mutant procaspase-1 and apopto-
sis induced by transfection of MCF-7 cells by normal p53 was
partially (over 60%) inhibited by mutant procaspase-1 (Fig.
5A). Inhibition of PTP-S2-induced apoptosis by mutant pro-
caspase-1 was not due to decrease in p53 protein induction
(Fig. 5B). PTP-S2 as well as p53-induced apoptosis in A549
human lung cancer cell line was also inhibited by mutant
procaspase-1 (data not shown). We found that apoptosis in-
duced by doxorubicin treatment of MCF-7 cells was partially
inhibited by mutant procaspase-1 (Fig. 6A). Apoptosis in-
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Fig. 5. Caspase-1 is required for PTP-S2-induced and p53-induced
apoptosis. A: E¡ect of coexpression of mutant caspase-1 (mCasp-1)
or control plasmid on apoptosis induced by caspase-1, caspase-3,
caspase-4, PTP-S2 or p53 in MCF-7 cells. Cells were ¢xed and pro-
cessed for immuno£uorescence after 48 h (PTP-S2, caspase-1, cas-
pase-3 and caspase-4) or 24 h (p53) of transfection. The total
amount of DNA transfected was kept constant. B: Expression of
mutant caspase-1 does not e¡ect induction of p53 by PTP-S2.
MCF-7 cells were transfected with PTP-S2 plasmid with or without
mutant caspase-1. After 48 h the cell lysates were subjected to im-
munoblotting with indicated antibodies.
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Fig. 4. PTP-S2-induced apoptosis requires p53 but not p73. A: Ef-
fect of cotransfection of p73DD, p53DD or control plasmid (C) on
PTP-S2-induced apoptosis in MCF-7 cells. B: Immunoblot showing
expression of p73DD and p53DD using T7 epitope antibody.
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duced by treatment of MCF-7 cells with cycloheximide or
staurosporine, which did not induce caspase-1 gene expression
(Fig. 6B) or p53 protein (Fig. 6C), was not inhibited by mu-
tant procaspase-1 (Fig. 6A). Thus, mutant procaspase-1 in-
hibited apoptosis induced by those agents which also induced
caspase-1 gene expression.
These results suggest that caspase-1 (or a related caspase
inhibited by mutant caspase-1) plays an important role in
mediating p53-dependent apoptosis. It is generally believed
that many genes induced transcriptionally contribute towards
p53-dependent apoptosis and no single gene is absolutely es-
sential. Therefore nearly complete inhibition of PTP-S2-in-
duced apoptosis by mutant caspase-1 is somewhat unex-
pected. Although other known transcriptional targets of p53
such as Apaf-1 may be induced by PTP-S2 expression, cas-
pase-1 seems to play a predominant role in PTP-S2-induced
apoptosis. Several studies have implicated the involvement of
caspase-3 in p53-mediated apoptosis. In our studies both
PTP-S2 as well as p53 induced apoptosis in MCF-7 cells,
which lack functional caspase-3 due to a deletion in the
gene [22], implying that caspase-3 is not essential for p53-
mediated apoptosis.
A functional p53-binding site has been identi¢ed in human
caspase-1 promoter [5]. No putative p53-binding site could be
identi¢ed in the 5P regulatory sequences or introns of murine
caspase-1 gene. These observations indicate that in murine
cells caspase-1 gene expression may not be regulated by p53.
Apoptosis induced by overexpression of p53 in NIH 3T3 cells
was not inhibited by caspase-1 family inhibitor YVAD-chlor-
omethylketone (cmk) but was inhibited by caspase-3 inhibitor
DEVD-cmk (70% inhibition). Thymocytes from caspase-1
knockout mice are sensitive to apoptosis induced by ionizing
radiation, which is p53-dependent [23]. Although cell type-
speci¢c di¡erences in apoptosis are possible it is likely that
in murine cells caspase-1 may not be a mediator of p53-de-
pendent apoptosis. Our results presented here suggest that
transcriptional activation of caspase-1 contributes towards
p53-dependent apoptosis in human cells.
In conclusion our results show that overexpression of PTP-
S2 increases the p53 protein level and activity resulting in
increased caspase-1 gene expression. Caspase-1 is required
for PTP-S2-induced and p53-dependent apoptosis. On the ba-
sis of these results we suggest that caspase-1 may be one of the
mediators of p53-dependent apoptosis.
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